Nearly one in every hundred children born in the UK will develop type 1 diabetes before the age of 20. For those with this autoimmune condition, life can become a daily management routine of insulin injections and blood sugar monitoring. But hope is on the horizon: NHS England has given its seal of approval for Teplizumab, a revolutionary new treatment designed to delay the onset of type 1 diabetes in certain individuals.
Teplizumab has been specifically indicated for people aged eight and over who are in stage 2 of type 1 diabetes. At this stage, patients may not yet be experiencing full-blown symptoms, but they will have developed autoantibodies and abnormal blood sugar levels. The treatment works by targeting the immune system, binding to specific T-cells that mistakenly attack insulin-producing beta cells in the pancreas.
Trials have shown that Teplizumab can delay the progression from stage 2 to stage 3 type 1 diabetes – where full-blown symptoms appear – for an average of two to three years. This extra time without diagnosis can make a significant difference to daily life, potentially reducing the risk of early complications and improving quality of life.
The treatment itself involves a 14-day course of daily intravenous infusions. Approximately 3,000 individuals in England are expected to be eligible for this innovative therapy over the next five years – those who could benefit from a delayed diagnosis and all its associated health advantages.
NICE has given its backing to Teplizumab after evaluating its effectiveness and cost-effectiveness. As the treatment is rolled out, it marks an important shift towards more proactive strategies in managing chronic diseases, offering new hope for families affected by type 1 diabetes.